Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Lucid Group Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Lucid Group Inc trades at $3.79 (market cap $1.51B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 8.3× Lucid Group Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Lucid Group Inc for 45 Days on average.
| HALO | LCID | |
|---|---|---|
Market Cap | $12.58B | $1.51B |
Volume | 2,179,278 | 12,333,745 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $21.92 |
52-Week Low | $61.63 | $3.82 |
Typical Hold Time | 1 Days | 45 Days |
Enterprise Value | $14.49B | $4.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lucid Group (LCID) trades at $3.82, down 1.8% on the day, with a bearish technical signal and weak fundamentals. The company reported a net loss of $2.70 billion in 2025, with negative gross and net income margins, and has missed earnings expectations for three consecutive quarters. Recent news highlights cost-saving initiatives and autonomous vehicle partnerships, but also delays in the Cosmos SUV launch and concerns over cash burn.
The outlook remains challenging due to persistent losses and high cash burn, though analyst consensus suggests potential upside with a $7.60 price target. Key risks include execution delays, competitive pressures, and the need for additional financing. Investor sentiment is cautious, with most analysts rating the stock Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
